Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients

Mov Disord. 2017 May;32(5):750-756. doi: 10.1002/mds.26931. Epub 2017 Feb 10.

Abstract

Objectives: A mutation in leucine-rich repeat kinase 2 is the most common cause of hereditary Parkinson's disease (PD), yet the neural mechanisms and the circuitry potentially involved are poorly understood.

Methods: We used different transcranial magnetic stimulation protocols to explore in the primary motor cortex the activity of intracortical circuits and cortical plasticity (long-term potentiation) in patients with the G2019S leucine-rich repeat kinase 2 gene mutation when compared with idiopathic PD patients and age-matched healthy subjects. Paired pulse transcranial magnetic stimulation was used to investigate short intracortical inhibition and facilitation and short afferent inhibition. Intermittent theta burst stimulation, a form of repetitive transcranial magnetic stimulation, was used to test long-term potentiation-like cortical plasticity. Leucine-rich repeat kinase 2 and idiopathic PD were tested both in ON and in OFF l-dopa therapy.

Results: When compared with idiopathic PD and healthy subjects, leucine-rich repeat kinase 2 PD patients showed a remarkable reduction of short intracortical inhibition in both ON and in OFF l-dopa therapy. This reduction was paralleled by an increase of intracortical facilitation in OFF l-dopa therapy. Leucine-rich repeat kinase 2 PD showed abnormal long-term potentiation-like cortical plasticity in ON l-dopa therapy.

Discussion: The motor cortex in leucine-rich repeat kinase 2 mutated PD patients is strongly disinhibited and hyperexcitable. These abnormalities could be a result of an impairment of inhibitory (gamma-Aminobutyric acid) transmission eventually related to altered neurotransmitter release. © 2017 International Parkinson and Movement Disorder Society.

Keywords: LRRK2; Parkinson disease; TMS; cortical plasticity; levodopa.

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Case-Control Studies
  • Cerebral Cortex / metabolism
  • Cerebral Cortex / physiopathology
  • Female
  • Humans
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
  • Levodopa / therapeutic use
  • Long-Term Potentiation / physiology*
  • Male
  • Middle Aged
  • Motor Cortex / metabolism
  • Motor Cortex / physiopathology*
  • Neural Inhibition / physiology*
  • Neural Pathways / metabolism
  • Neural Pathways / physiopathology
  • Neuronal Plasticity / physiology
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology*
  • Synaptic Transmission
  • Transcranial Magnetic Stimulation
  • gamma-Aminobutyric Acid / metabolism

Substances

  • Antiparkinson Agents
  • Levodopa
  • gamma-Aminobutyric Acid
  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2